XORTX extends deadline to complete Vectus acquisition to March

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/19/2026

1. VRNS
2. CRWV
3. JBHT
4. TSLA
5. SCHW
6. GPRK
7. TRV
8. TFC
9. AA
10. TECHM:IN

Go back to XORTX extends deadline to complete Vectus acquisition to March

XORTX Provides Update on Acquisition of Renal Anti-Fibrotic Therapeutic Program from Vectus Biosystems

February 4, 2026 6:00 PM EST

CALGARY, Alberta, Feb. 04, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (XORTX or the Company) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, announces that further to its press release of October 17, 2025 and an update on December 31, 2025, the Company has entered into an extension agreement with Vectus Biosystems Limited (Vectus) to allow further time to complete the acquisition of the Renal Anti-Fibrotic Therapeutic Program from Vectus (the Acquisition). The term sheet entered into October 17th (the Term Sheet) to acquire the... More